Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gottlieb

Showing results (451-460 of 523) with videos related to

Pageof 53
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2021
Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
The Journal of Rheumatology|July 9, 2008
Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature reviewLaura C Coates, R Rox Anderson, Oliver Fitzgerald, et al.
Journal of Cutaneous Medicine and Surgery|April 30, 2003
Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasisAlice B Gottlieb, Bruce Miller, Nicholas Lowe, et al.
The Journal of Rheumatology|June 3, 2014
The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meetingAlice B Gottlieb, April W Armstrong, Robin Christensen, et al.
Journal of Drugs in Dermatology : JDD|August 2, 2024
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body AreasAlice B Gottlieb, April Armstrong, Andrew Blauvelt, et al.
The Journal of Rheumatology|July 9, 2008
Clinical and genetic registries in psoriatic diseaseDafna D Gladman, Proton Rahman, Gerald G Krueger, et al.
BMC Rheumatology|May 21, 2024
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled studyAlexis Ogdie, Joseph F Merola, Philip J Mease, et al.
Lancet (London, England)|May 11, 2020
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trialIain B McInnes, Frank Behrens, Philip J Mease, et al.
JAMA Dermatology|February 26, 2025
Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With PsoriasisApril W Armstrong, Kathryn Lee, Danielle Yee, et al.
International Journal of Dermatology|August 21, 2025
Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 StudiesAfsaneh Alavi, Ziad Reguiai, Gregor B E Jemec, et al.
Pageof 53

Showing results (451-460 of 523) with videos related to

Sort By:
Pageof 53
Arthritis & Rheumatology (Hoboken, N.J.)|November 1, 2021
Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic ArthritisIain B McInnes, Proton Rahman, Alice B Gottlieb, et al.
The Journal of Rheumatology|July 9, 2008
Clues to the pathogenesis of psoriasis and psoriatic arthritis from imaging: a literature reviewLaura C Coates, R Rox Anderson, Oliver Fitzgerald, et al.
Journal of Cutaneous Medicine and Surgery|April 30, 2003
Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasisAlice B Gottlieb, Bruce Miller, Nicholas Lowe, et al.
The Journal of Rheumatology|June 3, 2014
The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meetingAlice B Gottlieb, April W Armstrong, Robin Christensen, et al.
Journal of Drugs in Dermatology : JDD|August 2, 2024
Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body AreasAlice B Gottlieb, April Armstrong, Andrew Blauvelt, et al.
The Journal of Rheumatology|July 9, 2008
Clinical and genetic registries in psoriatic diseaseDafna D Gladman, Proton Rahman, Gerald G Krueger, et al.
BMC Rheumatology|May 21, 2024
Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled studyAlexis Ogdie, Joseph F Merola, Philip J Mease, et al.
Lancet (London, England)|May 11, 2020
Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trialIain B McInnes, Frank Behrens, Philip J Mease, et al.
JAMA Dermatology|February 26, 2025
Validation of DermSat-7 for Assessing Treatment Satisfaction in Patients With PsoriasisApril W Armstrong, Kathryn Lee, Danielle Yee, et al.
International Journal of Dermatology|August 21, 2025
Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Pooled Pharmacokinetics and Safety Results From the SUNSHINE and SUNRISE Phase 3 StudiesAfsaneh Alavi, Ziad Reguiai, Gregor B E Jemec, et al.
Pageof 53